Literature DB >> 17361038

Isoform specific amyloid-beta protein precursor metabolism.

Ana Gabriela Henriques1, Sandra Isabel Vieira, Sandra Rebelo, Sara C T S Domingues, Edgar F da Cruz e Silva, Odete A B da Cruz e Silva.   

Abstract

Alzheimer's amyloid-beta protein precursor (AbetaPP) can occur in different isoforms, among them AbetaPP(751), which is the most abundant isoform in non-neuronal tissues, and AbetaPP(695), often referred to as the neuronal isoform. However, few isoform-specific roles have been addressed. In the work here described, AbetaPP isoforms, both endogenous and as cDNA fusions with green fluorescent protein (GFP), were used to permit isoform-specific monitoring in terms of intracellular processing and targeting. Differences were particularly marked in the turnover rates of the immature isoforms, with AbetaPP(751) having a faster turnover rate than AbetaPP(695) (0.8 h and 1.2 h respectively for endogenous proteins and 1.1 h and 2.3 h for transfected proteins). Hence, AbetaPP(751) matures faster. Additionally, AbetaPP(751) responded to both okadaic acid (OA) and phorbol 12-myristate 13-acetate (PMA), as determined by sAbetaPP production, with PMA inducing a more robust response. For the AbetaPP(695) isoform, however, although PMA produced a strong response, OA failed to elicit such an induction in sAbetaPP production, implicating isoform specificity in phosphorylation regulated events. In conclusion, it seems that the AbetaPP(695) isoform is processed/metabolized at a slower rate and responds differently to OA when compared to the AbetaPP(751) isoform. The relevance of isoform-specific processing in relation to Alzheimer's disease needs to be further investigated, given the predominance of the AbetaPP(695) isoform in neuronal tissues and isoform-specific alterations in expression levels associated with the pathology.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17361038     DOI: 10.3233/jad-2007-11112

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  7 in total

1.  The transcriptionally active amyloid precursor protein (APP) intracellular domain is preferentially produced from the 695 isoform of APP in a {beta}-secretase-dependent pathway.

Authors:  Nikolai D Belyaev; Katherine A B Kellett; Caroline Beckett; Natalia Z Makova; Timothy J Revett; Natalia N Nalivaeva; Nigel M Hooper; Anthony J Turner
Journal:  J Biol Chem       Date:  2010-10-20       Impact factor: 5.157

2.  Alphabeta hinders nuclear targeting of AICD and Fe65 in primary neuronal cultures.

Authors:  A G Henriques; S I Vieira; E F da Cruz e Silva; O A B da Cruz e Silva
Journal:  J Mol Neurosci       Date:  2009-04-02       Impact factor: 3.444

3.  S655 phosphorylation enhances APP secretory traffic.

Authors:  Sandra Isabel Vieira; Sandra Rebelo; Sara Catarina Domingues; Edgar F da Cruz e Silva; Odete A B da Cruz e Silva
Journal:  Mol Cell Biochem       Date:  2009-04-21       Impact factor: 3.396

4.  APP Binds to the EGFR Ligands HB-EGF and EGF, Acting Synergistically with EGF to Promote ERK Signaling and Neuritogenesis.

Authors:  Odete A B da Cruz E Silva; Sandra I Vieira; Joana F da Rocha; Luísa Bastos; Sara C Domingues; Ana R Bento; Uwe Konietzko
Journal:  Mol Neurobiol       Date:  2020-10-02       Impact factor: 5.590

5.  Lipid rafts and Alzheimer's disease: protein-lipid interactions and perturbation of signaling.

Authors:  David A Hicks; Natalia N Nalivaeva; Anthony J Turner
Journal:  Front Physiol       Date:  2012-06-22       Impact factor: 4.566

6.  Identification of a novel human LAP1 isoform that is regulated by protein phosphorylation.

Authors:  Mariana Santos; Sara C Domingues; Patrícia Costa; Thorsten Muller; Sara Galozzi; Katrin Marcus; Edgar F da Cruz e Silva; Odete A da Cruz e Silva; Sandra Rebelo
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

7.  Complexing Aβ prevents the cellular anomalies induced by the Peptide alone.

Authors:  A G Henriques; J M Oliveira; B Gomes; R Ruivo; E F da Cruz e Silva; O A B da Cruz e Silva
Journal:  J Mol Neurosci       Date:  2014-03-07       Impact factor: 3.444

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.